ClinicalTrials.gg
Active, not recruitingNCT02466737INSEMAUpdated May 1, 2026

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery

An interventional study of no axillary surgery versus SLNB and SLNB versus completion ALND in Breast Cancer, sponsored by University of Rostock. Active, not recruiting at 150 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Rostock · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,505
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 196 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Enrollment
8th of 580
5,505 · median 273
Started
2015
with 25 others
No phase
102 of 678
28 open now
Primary completion
2024-08
later than 24 of 195 live
Registered
344th of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 8th largest by enrollment of the 580 interventional ones that give a count, is one of 26 that started in 2015, is one of 102 with no phase, reaches primary completion later than 24 of the 195 other live ones, and was the 344th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Although there is no doubt that the presence of lymph node metastases worsens prognosis of a patient, unambiguous evidence to support lymph node dissection is still lacking. For many solid tumors, the role of lymph node dissection is yet controversial, and may depend on the tumor type and the stage of patient presentation for diagnosis. Axillary surgery for breast cancer is now considered as staging procedure that does not seem to influence breast cancer mortality. Women with breast cancer have benefitted greatly from a series of carefully performed randomized controlled trial focusing on axillary surgery. The objective of INSEMA is to show that less axillary surgery is better, in that oncological outcomes are the same and less surgical intervention will result in fewer surgical complications.

Read the detailed description

Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement.

The goal of the present study is to show that early-stage breast cancer patients with reduced extent of axillary surgery are not inferior regarding disease-free survival outcome compared with the standard arm. All patients will be first randomized to either no axillary surgical intervention or axillary sentinel lymph node biopsy (SLNB). Patients with SLNB and pN+(sn) status will be secondly randomized to either SLNB alone or completion axillary lymph node dissection (ALND) in cases with less than four involved nodes (1-3 macrometastases). Patients with four or more metastatic sentinel lymph nodes should undergo completion ALND.

Postoperative systemic treatment should be based on local multidisciplinary tumor board recommendation according to the current German AGO and S3 guidelines. For women who are treated with breast-conserving surgery, the most common site of local recurrence is the conserved ipsilateral breast itself. Thus, whole-breast radiation therapy after breast-conserving surgery is mandatory and should be performed according to the current guidelines (S3, AGO, DEGRO).

During follow-up, patients will be assessed for disease recurrence according to standard clinical practice. History and physical examination will be performed every 6 months for the first 36 months and yearly thereafter. Annual mammography and sonography will be required; other testing will be based on symptoms and investigator preference. The total number of patients to be randomized into the trial will be approximately 7,095. An event-driven final efficacy analysis will be performed per-protocol for two primary objectives.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • axillary surgery
  • sentinel lymph node biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written prior to beginning breast-conserving surgery, including expected cooperation of the patients for follow-up, must be obtained and documented according to the local regulatory requirements
  • confirmed unilateral primary invasive carcinoma of the breast (core or open biopsy). Multifocal or multicentric tumors are allowed if breast-conserving surgery is planned
  • Age at diagnosis at least 18 years
  • Preoperative imaging techniques with estimated tumor size of \<5 cm (iT1/iT2 irrespective of hormone sensitivity or status)
  • Clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0)
  • In cases with cN0 and iN+, a negative core biopsy or fine needle aspiration (FNA) biopsy of the sonographically suspected lymph node is required before randomization
  • No clinical evidence for distant (M0)
  • Planned breast-conserving surgery (R0 resection) with postoperative external whole-breast irradiation (conventional fractionation or hypofractionation)

Exclusion criteria

Exclusion Criteria:

  • History of within last 5 years, except curatively treated basalioma of the skin and carcinoma in situ of the cervix
  • Time since core >3 months (optimal \<1 month)
  • Previous and already () treated invasive breast carcinoma
  • Histologically non-invasive breast carcinoma
  • cT3/T4 or iT3/T4 tumors
  • pregnant or lactating patients
  • Planned total mastectomy (e.g. multicentric tumors )
  • Planned intraoperative radiotherapy (e.g. Intrabeam) or postoperative partial breast irradiation (e.g. multicatheter technique) alone; both procedures are allowed as boost techniques
  • Male patients
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
5,505 participants (actual)

Study arms

  • Experimental
    no axillary surgery

    Procedure: no axillary surgery versus SLNB

  • Active comparator
    sentinel lymph node biopsy

    standard arm in first randomization

    Procedure: no axillary surgery versus SLNB

  • Experimental
    sentinel lymph node biopsy alone

    Procedure: SLNB versus completion ALND

  • Active comparator
    completion axillary lymph node dissection

    standard arm in second randomization

    Procedure: SLNB versus completion ALND

Interventions

  • Procedureno axillary surgery versus SLNB

    in cases with newly diagnosed breast cancer and clinically negative axillary status

  • ProcedureSLNB versus completion ALND

    in cases with 1-3 macrometastases in sentinel lymph nodes

06

What researchers measure

Primary outcomes

  1. invasive disease-free survival (IDFS) after breast-conserving surgery

    non-inferiority question

    Time frame: 5 years

07

Study locations

150 sites
  • Universitätsfrauenklinik Salzburg
    Salzburg, State of Salzburg 5020, Austria
  • BGZ Dornbirn, Gynäkologie
    Dornbirn, 6850, Austria
  • LKH Uni-Klinikum Graz, Gynäkologie
    Graz, 8036, Austria
  • Ordensklinikum-BHS
    Linz, 4010, Austria
  • Kepler Universitätsklinikum
    Linz, 4020, Austria
  • KH der Barmherzigen Brüder
    Saint Veit/Glan, 9300, Austria
  • Hanusch-Krankenhaus, Brustzentrum
    Vienna, 1140, Austria
  • Landes-Krankenhaus Wolfsberg, Chirurgie
    Wolfsberg, 9400, Austria
  • Ostalb-Klinikum, Brustzentrum Aalen
    Aalen, Baden-Wurttemberg 73430, Germany
  • Caritas-Krankenhaus Brustzentrum Tauberfranken
    Bad Mergentheim, Baden-Wurttemberg 97980, Germany
  • Klinikum Mittelbach Brustzentrum
    Baden-Baden, Baden-Wurttemberg 76532, Germany
  • Sana-Klinikum Biberach
    Biberach, Baden-Wurttemberg 88400, Germany
  • Krankenhaus Bietigheim
    Bietigheim, Baden-Wurttemberg 74321, Germany
  • Klinikum Böblingen
    Böblingen, Baden-Wurttemberg 71032, Germany
  • Fürst-Stirum-Klinik
    Bruchsal, Baden-Wurttemberg 76646, Germany
  • Brustzentrum Donau-Riß
    Ehingen, Baden-Wurttemberg 89584, Germany
  • Klinikum Esslingen
    Esslingen am Neckar, Baden-Wurttemberg 73730, Germany
  • Universitätsklinikum Freiburg
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Frauenklinik Freudenstadt
    Freudenstadt, Baden-Wurttemberg 72250, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Städtisches Klinikum Karlsruhe
    Karlsruhe, Baden-Wurttemberg 76133, Germany
  • ViDia Christliche Kliniken, Diakonissenkrankenhaus Karlsruhe
    Karlsruhe, Baden-Wurttemberg 76199, Germany
  • St. Elisabethen Krankenhaus
    Loerrach, Baden-Wurttemberg 79539, Germany
  • Klinikum Ludwigsburg
    Ludwigsburg, Baden-Wurttemberg 71640, Germany
  • Helios Klinik Pforzheim
    Pforzheim, Baden-Wurttemberg 75175, Germany
  • Siloah St. Trudpert Klinikum
    Pforzheim, Baden-Wurttemberg 75179, Germany
  • Klinikum am Steinenberg
    Reutlingen, Baden-Wurttemberg 72764, Germany
  • Helios Klinik Rottweil
    Rottweil, Baden-Wurttemberg 78628, Germany
  • Rems-Murr Klinik
    Schorndorf, Baden-Wurttemberg 73614, Germany
  • Klinikum Tuttlingen
    Tuttlingen, Baden-Wurttemberg 78532, Germany
  • Universitätsfrauenklinik
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Universitätsfrauenklinik Ulm
    Ulm, Baden-Wurttemberg 89075, Germany
  • Schwarzwald-Baar Klinikum
    Villingen-Schwenningen, Baden-Wurttemberg 78050, Germany
  • Rems-Murr Kliniken
    Winnenden, Baden-Wurttemberg 71364, Germany
  • Klinikum St. Marien
    Amberg, Bavaria 92224, Germany
  • AN regiomed Klinikum Ansbach
    Ansbach, Bavaria 91522, Germany
  • Klinikum Aschaffenburg
    Aschaffenburg, Bavaria 63739, Germany
  • Hämatologisch-onkologische Praxis
    Augsburg, Bavaria 86150, Germany
  • Klinikum Bayreuth GmbH, Frauenklinik
    Bayreuth, Bavaria 95445, Germany
  • Kreisklinik Ebersberg
    Ebersberg, Bavaria 85560, Germany
  • Gynäkologische Praxis
    Eggenfelden, Bavaria 84307, Germany
  • Klinikum Fürth
    Fürth, Bavaria 90766, Germany
  • Klinikum Kempten-Oberallgäu
    Kempten (Allgäu), Bavaria 87439, Germany
  • Klinikum Landshut
    Landshut, Bavaria 84034, Germany
  • Klinikum Fichtelgebirge gGmbH, Brustzentrum
    Marktredwitz, Bavaria 95615, Germany
  • Klinikum Memmingen
    Memmingen, Bavaria 87700, Germany
  • Klinikum der Universität München
    München, Bavaria 80337, Germany
  • Klinikum Harlaching, Frauenklinik
    München, Bavaria 81545, Germany
  • Klinikum Passau
    Passau, Bavaria 94032, Germany
  • Frauenklinik der Universität Regensburg, Caritas-Krankenhaus St. Josef
    Regensburg, Bavaria 93053, Germany
  • Klinikum Starnberg
    Starnberg, Bavaria 82319, Germany
  • Klinikum Traunstein
    Traunstein, Bavaria 83278, Germany
  • Kliniken Nordoberpfalz AG, Brustzentrum Weiden
    Weiden, Bavaria 92637, Germany
  • Rotkreuzklinik Würzburg
    Würzburg, Bavaria 97070, Germany
  • Klinikum Mitte, Missio Brustzentrum
    Würzburg, Bavaria 97074, Germany
  • Städtisches Klinikum Brandenburg
    Brandenburg an der Havel, Brandenburg 14770, Germany
  • Carl-Thiem-Klinikum
    Cottbus, Brandenburg 03046, Germany
  • Ev. Krankenhaus, Frauenklinik
    Ludwigsfelde, Brandenburg 14974, Germany
  • Klinikum Ernst von Bergmann
    Potsdam, Brandenburg 14467, Germany
  • Universitätsklinikum Hamburg, Brustzentrum
    Hamburg, Free and Hanseatic City of Hamburg 20246, Germany
  • Agaplesion Diakonieklinikum, Brustzentrum
    Hamburg, Free and Hanseatic City of Hamburg 20259, Germany
  • Gynäkologische Praxisklinik Harburg
    Hamburg, Free and Hanseatic City of Hamburg 21673, Germany
  • Albertinen-Krankenhaus, Brustzentrum
    Hamburg, Free and Hanseatic City of Hamburg 22457, Germany
  • St. Joseph Stift
    Bremen, Free Hanseatic City of Bremen 28209, Germany
  • DIAKO Krankenhaus Bremen
    Bremen, Free Hanseatic City of Bremen 28239, Germany
  • Agaplesion Markus Krankenhaus
    Frankfurt am Main, Hesse 60431, Germany
  • Universitätsklinikum Brustzentrum
    Frankfurt am Main, Hesse 60590, Germany
  • Klinikum Frankfurt Höchst
    Frankfurt am Main, Hesse 65929, Germany
  • Main-Kinzig-Kliniken Gelnhausen
    Gelnhausen, Hesse 63571, Germany
  • Klinikum Hanau GmbH
    Hanau, Hesse 63450, Germany
  • Kreiskrankenhaus Bergstraße gGmbH
    Heppenheim an der Bergstrasse, Hesse 64646, Germany
  • Elisabeth Krankenhaus Kassel
    Kassel, Hesse 34117, Germany
  • Klinikum Kassel
    Kassel, Hesse 34125, Germany
  • Sana Klinikum Offenbach
    Offenbach, Hesse 63069, Germany
  • St. Josefs-Hospital, Frauenklinik
    Wiesbaden, Hesse 65189, Germany
  • Asklepios Paulinenklinik
    Wiesbaden, Hesse 65197, Germany
  • Helios Dr. Horst Schmidt Klinikum
    Wiesbaden, Hesse 65199, Germany
  • AKH Celle, Brustzentrum
    Celle, Lower Saxony 29223, Germany
  • Franziskus Hospital Harderberg
    Georgsmarienhütte, Lower Saxony 49124, Germany
  • Helios Klinikum Gifhorn
    Gifhorn, Lower Saxony 38518, Germany
  • Henriettenstiftung Frauenklinik
    Hanover, Lower Saxony 30559, Germany
  • Vinzenzkrankenhaus Hannover
    Hanover, Lower Saxony 30559, Germany
  • MHH Frauenklinik
    Hanover, Lower Saxony 30625, Germany
  • St. Bernward Krankenhaus
    Hildesheim, Lower Saxony 31134, Germany
  • Bonifatius-Hospital, Brustzentrum
    Lingen, Lower Saxony 49808, Germany
  • Euregio-Klinik Brustzentrum Nordhorn
    Nordhorn, Lower Saxony 48527, Germany
  • Agaplesion Ev. Klinikum, Brustzentrum Schaumburg
    Obernkirchen, Lower Saxony 31683, Germany
  • Klinikum Osnabrück
    Osnabrück, Lower Saxony 49076, Germany
  • Diakoniekrankenhaus, Frauenklinik
    Rotenburg (Wümme), Lower Saxony 27356, Germany
  • Klinikum Wolfsburg, Frauenklinik
    Wolfsburg, Lower Saxony 38440, Germany
  • Universität Greifswald, Frauenklinik
    Greifswald, Mecklenburg-Vorpommern 17475, Germany
  • Dietrich Bonhoeffer Klinikum, Brustzentrum
    Neubrandenburg, Mecklenburg-Vorpommern 17036, Germany
  • Universitäts-Frauenklinik
    Rostock, Mecklenburg-Vorpommern 18059, Germany
  • Helios Kliniken Schwerin
    Schwerin, Mecklenburg-Vorpommern 19049, Germany
  • Augusta-Klinik
    Bochum, Nordrhein 44791, Germany
  • Universitätsfrauenklinik Bonn
    Bonn, Nordrhein 53105, Germany
  • Marienhospital Bottrop
    Bottrop, Nordrhein 46236, Germany
  • Uniklinik Köln
    Cologne, Nordrhein 50931, Germany
  • St. Elisabeth Krankenhaus, Brustzentrum
    Cologne, Nordrhein 50935, Germany
  • Frauenklinik der H.-Heine-Universität
    Düsseldorf, Nordrhein 40225, Germany

Showing the first 100 of 150 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, Wolter K, Hildebrandt G, Gerber B. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd. 2017 Feb;77(2):149-157. doi: 10.1055/s-0042-122853. PubMed 28331237 ↗
  • Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, Kuhn T, Zierhut D, Sedlmayer F, Kaiser J, Reitsamer R, Heil J, Nekljudova V, Bekes I, Loibl S, Reimer T. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):683-693. doi: 10.1016/j.ijrobp.2020.04.042. Epub 2020 May 11. PubMed 32437921 ↗
  • Reimer T, Stachs A, Veselinovic K, Polata S, Muller T, Kuhn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahm DM, Thill M, Nekljudova V, Krug D, Loibl S, Gerber B; INSEMA investigators. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2022 Nov 25;55:101756. doi: 10.1016/j.eclinm.2022.101756. eCollection 2023 Jan. PubMed 36457648 ↗
  • Marme F, Krieghoff-Henning E, Gerber B, Schmitt M, Zahm DM, Bauerschlag D, Forstbauer H, Hildebrandt G, Ataseven B, Brodkorb T, Denkert C, Stachs A, Krug D, Heil J, Golatta M, Kuhn T, Nekljudova V, Gaiser T, Schonmehl R, Brochhausen C, Loibl S, Reimer T, Brinker TJ. Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images. Eur J Cancer. 2023 Dec;195:113390. doi: 10.1016/j.ejca.2023.113390. Epub 2023 Oct 18. PubMed 37890350 ↗
  • Reimer T, Stachs A, Veselinovic K, Kuhn T, Heil J, Polata S, Marme F, Muller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm DM, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med. 2025 Mar 13;392(11):1051-1064. doi: 10.1056/NEJMoa2412063. Epub 2024 Dec 12. PubMed 39665649 ↗
  • Reimer T, Stachs A, Veselinovic K, Kuehn T, Heil J, Polata S, Marme F, Trapp E, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Stahl N, Thill M, Strittmatter HJ, Mueller T, Golatta M, Zahm DM, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. NPJ Breast Cancer. 2026 Jan 27;12(1):19. doi: 10.1038/s41523-026-00902-7. PubMed 41593108 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Aug 2024, 107 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 107 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2015
First posted
Jun 9, 2015
StartActual
Sep 2015
Primary completionActual
Aug 30, 2024
CompletionEst.
Dec 2029
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02466737
Lead sponsor
University of Rostock
Collaborators
German Cancer Aid, GBG Forschungs GmbH
Responsible party
Toralf Reimer, MD PhD (Prof. Dr. Toralf Reimer, University of Rostock) — Principal investigator
First posted
Jun 9, 2015
Start date
Sep 2015
Primary completion
Aug 30, 2024
Completion
Dec 2029 (estimated)
Last update
May 1, 2026

Study contacts

Toralf Reimer, MD, PhD
study chair · University Medical Center Rostock

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion